Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
NDL | Ann: Change of Company Name | 31/05/13 | 0 | 802 | |||
|
|||||||
NDL | Ann: Results of Meeting | 22/05/13 | 0 | 717 | |||
|
|||||||
NDL | testing 4c. again | 21/05/13 | 20 | 4.3K | |||
|
|||||||
NDL | Ann: Japanese patent granted | 13/05/13 | 0 | 632 | |||
|
|||||||
NDL | Ann: Appendix 4C - quarterly | 26/04/13 | 0 | 608 | |||
|
|||||||
NDL | Ann: Change of Director's Interest Notice | 22/04/13 | 0 | 572 | |||
|
|||||||
NDL | Ann: Notice of Extraordinary General Meeting/Prox | 19/04/13 | 0 | 496 | |||
|
|||||||
NDL | Ann: Becoming a substantial holder x 3 | 17/04/13 | 0 | 407 | |||
|
See All Discussions